Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors

被引：19

作者：

Kawamura K. ^{[1
,3
]}

Bahar R. ^{[1
,3
]}

Natsume W. ^{[1
,2
,3
]}

Sakiyama S. ^{[3
]}

Tagawa M. ^{[1
,3
]}

机构：

[1] Division of Pathology, Chiba Cancer Center Research Institute, Chiba

[2] Department of Biology, Toho University, Funabashi

[3] Chiba Cancer Center Research Institute, Chiba

来源：

Cancer Gene Therapy | 2002年 / 9卷 / 1期

基金：

日本学术振兴会; 日本科学技术振兴机构;

关键词：

Colon carcinoma; IL-10; Immune suppression;

D O I：

10.1038/sj.cgt.7700418

中图分类号：

学科分类号：

摘要：

Interleukin-10 (IL-10) is a T helper type 2 (Th2) cytokine that suppresses Th1-mediated, cell-mediated immune responses and reciprocally enhances antibody-mediated responses. Previous studies, however, demonstrated that forced expression of the IL-10 gene in tumor cells could unexpectedly produce antitumor effects. We then examined whether tumor-derived IL-10 could modulate systemic immune responses. Murine colon carcinoma (Colon 26) cells that were retrovirally transduced with the murine IL-10 gene (Colon 26/IL-10) were inoculated in syngeneic immunocompetent or T cell-defective nude mice. Growth of Colon 26/IL-10 tumors was augmented in immunocompetent and, to less extent, in nude mice compared with that of wild-type tumors developed in respective mice. Growth of wild-type tumors was accelerated to the same level as that of Colon 26/IL-10 tumors when wild type and Colon 26/IL-10 cells were respectively inoculated in different flanks of the same immunocompetent mice. This enhanced growth of wild-type tumors was not observed in nude mice. Immunocompetent mice that had rejected IL-2- or IL-12-secreting Colon 26 cells developed protective immunity and became completely resistant to wild-type Colon 26 cells subsequently challenged. However, some of the mice that had rejected IL-2 or IL-12 producers developed Colon 26/IL-10 tumors inoculated thereafter. The present study showed that production of IL-10 from tumor cells impaired T cell- and non-T cell-mediated systemic antitumor immunity in hosts.

引用

页码：109 / 115

页数：6

共 26 条

[1]

Abbas A.K., Murphy K.M., Sher A., Functional diversity of helper T lymphocytes, Nature, 383, pp. 787-793, (1996)

[2]

Tagawa M., Cytokine therapy for cancer, Curr Pharm Des, 6, pp. 681-699, (2000)

[3]

Roth J.A., Cristiano R.J., Gene therapy for cancer: What have we done and where are we going?, J Natl Cancer Inst, 89, pp. 21-39, (1997)

[4]

Prud'homme G.J., Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors, J Gene Med, 2, pp. 222-232, (2000)

[5]

Moore K.W., O'Garra A., De Waal Malefyt R., Vieira P., Mosmann T.R., Interleukin-10, Annu Rev Immunol, 11, pp. 165-190, (1993)

[6]

Whalen J.D., Lechman E.L., Carlos C.A., Et al., Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws, Immunol, 162, pp. 3625-3632, (1999)

[7]

Shinozaki K., Yahata H., Tanji H., Et al., Allograft transduction of IL-10 prolongs survival following orthotopic liver transplantation, Gene Ther, 6, pp. 816-822, (1999)

[8]

Wang L., Goillot E., Tepper R.I., IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo, Cell Immunol, 159, pp. 152-169, (1994)

[9]

Hishii M., Nitta T., Ishida H., Et al., Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro, Neurosurg, 37, pp. 1160-1167, (1995)

[10]

Blay J.-Y., Burdin N., Rousset F., Et al., Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor, Blood, 82, pp. 2169-2174, (1993)

← 1 2 3 →